MEDIPHARMA: what changed
What changed
MEDIPHARMA
NACE 64.210, Activities of holding companies
filed annual accounts (NBB)
Net result for the year
€94,281
2024 · €149,317-€55,036
Equity
€2.0m
2024 · €2.0m+€94,281
Cash
€1,830
2024 · -+€1,830
Balance sheet total
€2.7m
2024 · €2.7m+€4,287
Largest movements
Assets
No asset line moved by more than 1% of the balance sheet total.
Equity and liabilities
- Profit (loss) carried forward +€94,281
up €94,281 (+29.2%), from €322,883 to €417,164
- Debts after one year -€56,427
down €56,427 (-32.8%), from €171,777 to €115,350
Income statement
- Gross operating margin -€89,361
down €89,361 (-37.4%), from €239,133 to €149,772
- Taxes -€18,008
down €18,008 (-34.7%), from €51,888 to €33,881
- Financial charges -€8,950
down €8,950 (-31.6%), from €28,307 to €19,357
- Depreciation -€6,800
down €6,800 (-93.4%), from €7,280 to €479
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
€149,317
Gross operating margin
-€89,361
Depreciation
+€6,800
Other operating charges
+€567
Financial charges
+€8,950
Taxes
+€18,008
Result 2025
€94,281
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
+€77,821
Investment
€0
Financing
-€75,991
Cash 2024
€0
From operations (derived)
+€77,821
Net result for the year
+€94,281
Depreciation
+€479
Receivables within one year
-€3,326
Deferred charges and accrued income
+€389
Trade debts
+€4,187
Tax, wage and social debts
-€2,291
Other debts
-€8,359
Accrued charges and deferred income
-€7,539
Financing
-€75,991
Debts after one year
-€56,427
Current portion of long-term debt
-€4,273
Short-term financial debts
-€15,292
Cash 2025
€1,830
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,704,055 | €2,708,342 | +€4,287 | +0.2% |
| Fixed assets | 21/28 | €2,701,656 | €2,701,176 | -€479 | 0.0% |
| Tangible fixed assets | 22/27 | €479 | - | -€479 | |
| Furniture and vehicles | 24 | €479 | - | -€479 | |
| Financial fixed assets | 28 | €2,701,176 | €2,701,176 | = | 0.0% |
| Current assets | 29/58 | €2,399 | €7,166 | +€4,767 | +199% |
| Amounts receivable within one year | 40/41 | €161 | €3,487 | +€3,326 | +2,064% |
| Trade receivables | 40 | - | €2,360 | +€2,360 | |
| Other amounts receivable | 41 | €161 | €1,127 | +€966 | +599% |
| Cash at bank and in hand | 54/58 | - | €1,830 | +€1,830 | |
| Deferred charges and accrued income | 490/1 | €2,238 | €1,849 | -€389 | -17.4% |
| Total equity and liabilities | 10/49 | €2,704,055 | €2,708,342 | +€4,287 | +0.2% |
| Equity | 10/15 | €1,952,974 | €2,047,255 | +€94,281 | +4.8% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €1,617,691 | €1,617,691 | = | 0.0% |
| Distributable reserves | 133 | €1,617,691 | €1,617,691 | = | 0.0% |
| Profit (loss) carried forward | 14 | €322,883 | €417,164 | +€94,281 | +29.2% |
| Amounts payable | 17/49 | €751,081 | €661,087 | -€89,994 | -12.0% |
| Amounts payable after more than one year | 17 | €171,777 | €115,350 | -€56,427 | -32.8% |
| Financial debts | 170/4 | €171,777 | €115,350 | -€56,427 | -32.8% |
| Amounts payable within one year | 42/48 | €563,495 | €537,467 | -€26,028 | -4.6% |
| Current portion of amounts payable after more than one year | 42 | €85,699 | €81,427 | -€4,273 | -5.0% |
| Financial debts | 43 | €27,064 | €11,772 | -€15,292 | -56.5% |
| Credit institutions | 430/8 | €27,064 | €11,772 | -€15,292 | -56.5% |
| Trade debts | 44 | - | €4,187 | +€4,187 | |
| Suppliers | 440/4 | - | €4,187 | +€4,187 | |
| Taxes, remuneration and social security | 45 | €16,524 | €14,232 | -€2,291 | -13.9% |
| Taxes | 450/3 | €16,524 | €14,232 | -€2,291 | -13.9% |
| Other amounts payable | 47/48 | €434,208 | €425,849 | -€8,359 | -1.9% |
| Accrued charges and deferred income | 492/3 | €15,809 | €8,270 | -€7,539 | -47.7% |
| Non-recurring operating income | 76A | - | €2,360 | +€2,360 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €7,280 | €479 | -€6,800 | -93.4% |
| Other operating charges | 640/8 | €2,341 | €1,774 | -€567 | -24.2% |
| Gross operating margin | 9900 | €239,133 | €149,772 | -€89,361 | -37.4% |
| Operating profit (loss) | 9901 | €229,512 | €147,518 | -€81,994 | -35.7% |
| Financial charges | 65/66B | €28,307 | €19,357 | -€8,950 | -31.6% |
| Recurring financial charges | 65 | €28,307 | €19,357 | -€8,950 | -31.6% |
| Profit (loss) for the period before taxes | 9903 | €201,206 | €128,162 | -€73,044 | -36.3% |
| Income taxes | 67/77 | €51,888 | €33,881 | -€18,008 | -34.7% |
| Profit (loss) for the period | 9904 | €149,317 | €94,281 | -€55,036 | -36.9% |
| Profit (loss) for the period to be appropriated | 9905 | €149,317 | €94,281 | -€55,036 | -36.9% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.